



PATENT APPLICATION

Atty. Docket No.12879/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Dr. Gautam Vinod Daftery, et al.

Application No.: 10/748,094

Filed: December 31, 2003

Examiner: Unassigned

Group Art Unit: Unassigned

For: NON-PEGYLATED LONG-CIRCULATING LIPOSOMES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). It is believed that no fees other than those indicated below are due, but authorization is hereby given to charge any additional fees due, or to credit any overpayment, to deposit account 11-0600.

This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d) before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.

Since this application was filed after June 30, 2003, copies of U.S. references are not included.

Respectfully submitted,

KENYON & KENYON




Teresa A. Lavenue

Registration No. 47,737

Date: 3/12/04

Kenyon & Kenyon & Kenyon
1500 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 220-4200
Facsimile: (202) 220-4201



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/748,094
Filing Date	December 31, 2003
First Named Inventor	Dr. Gautam Vinod Daftary, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	12879/2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 4,501,728	Feb. 26, 1995	Geho, et al.	
		US- 4,769,250	Sept. 6, 1988	Forssen	
		US- 4,880,635	Nov. 14, 1989	Janoff, et al.	
		US- 4,920,016	Apr. 24, 1990	Allen, et al.	
		US- 5,013,556	May 7, 1991	Woodle, et al.	
		US- 5,316,771	May 31, 1994	Barenholz et al.	
		US- 5,676,971	Oct. 14, 1997	Yoshioka, et al.	
		US- 5,756,122	May 26, 1998	Thierry, et al.	
		US- 6,083,530	Jul. 4 2000	Mayer, et al.	
		US- 6,132,763	Oct. 17, 2000	Fisher	
		US- 6,627,623	Sept. 30, 2003	Ho, et al.	
		US- 6,638,504	Oct. 28, 2003	Lukanidin	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	10/748,094
Filing Date	December 31, 2003
First Named Inventor	Dr. Gautam Vinod Daftary, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	12879/2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kenneth B. GORDON, "Cancer", <u>Hand-Foot Syndrome Associated with Liposome-Encapsulated Doxorubicin Therapy</u> , vol. 75, no. 8, pgs. 2169-2173, (1995)	
		Ruey-Long Hong, et al., "Clinical Cancer Research", <u>Direct Comparison of Liposomal Doxorubicin with or without Polyethylene Glycol Coating in C-26 Tumor-bearing Mice: Is Surface Coating with Polyethylene Glycol Beneficial</u> , vol. 5, pgs. 3645-3652, (1999)	
		Alberto A. Gabizon, M.D., Ph.D., "Cancer Investigation" <u>Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy</u> , vol. 19, no. 4, pgs. 424-436, (2001)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.